Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M. Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market ...
Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results